Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Resolution of severe MMF-related gastrointestinal adverse events following conversion to enteric-coated mycophenolate sodium.

Suwelack B, Gabriels G, Volmer S, Hillebrand U, Hohage H, Pohle T.

Transplantation. 2005 Apr 27;79(8):987-8. No abstract available.

PMID:
15849557
2.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.

Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.

Transplantation. 2007 Feb 27;83(4):417-24.

PMID:
17318074
3.

Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.

Abbud-Filho M, Girón F, Hernández E, Juarez F, Liendo C, Novoa P, Toledo M; Myproms Latam Study Group.

Transplant Proc. 2004 Jul-Aug;36(6):1647-9.

PMID:
15350440
4.

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.

Transplant Proc. 2004 Mar;36(2 Suppl):524S-527S.

PMID:
15041401
5.

Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.

Calvo N, Sanchez-Fructuoso AI, Conesa J, Moreno A, Barrientos A.

Transplant Proc. 2006 Oct;38(8):2396-7.

PMID:
17097945
6.

Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.

Nashan B, Suwelack B, Ivens K, Arns W, Lhotta K, Bourbigot B, Budde K, Fischer W, Pietruck F; ERL2405-DE02 Study Group.

Transplant Proc. 2006 Nov;38(9):2856-9.

PMID:
17112848
7.

Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.

Cofan F, Rosich E, Arias M, Torregrosa V, Oppenheimer F, Campistol JM.

Transplant Proc. 2007 Sep;39(7):2179-81.

PMID:
17889130
8.

Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.

Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M; myPROMS LatAm Study Group.

Transplant Proc. 2005 Mar;37(2):916-9.

PMID:
15848574
9.

Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.

Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, Cooper M, Langone AJ, Tomlanovich SJ.

Transplantation. 2007 Dec 15;84(11):1443-51.

PMID:
18091520
10.

Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.

Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.

Transplant Proc. 2007 Sep;39(7):2194-6.

PMID:
17889135
11.
12.
13.

Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).

Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M, Seifu Y, Marrast AC, Neumayer HH; ERL B302 Study Group.

Clin Nephrol. 2006 Aug;66(2):103-11.

PMID:
16939066
14.

Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients.

Salvadori M; ERL 8301 Study Group.

Transplant Proc. 2005 Mar;37(2):909-11.

PMID:
15848572
15.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study.

Dumortier J, Gagnieu MC, Salandre J, Guillaud O, Guillem P, Adham M, Boillot O.

Liver Transpl. 2006 Sep;12(9):1342-6.

16.

Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.

Kamar N, Oufroukhi L, Faure P, Ribes D, Cointault O, Lavayssiere L, Nogier MB, Esposito L, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Oct;20(10):2231-6. Epub 2005 Jul 26.

PMID:
16046517
17.

Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.

Tedesco-Silva H, Bastien MC, Choi L, Felipe C, Campestrini J, Picard F, Schmouder R.

Transplant Proc. 2005 Mar;37(2):852-5.

PMID:
15848554
18.

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M; ERL B301 Study Groups.

Am J Transplant. 2004 Feb;4(2):231-6.

19.

Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.

Budde K, Knoll G, Curtis J, Kahana L, Pohanka E, Seifu Y, Neumayer HH.

Transplant Proc. 2005 Mar;37(2):912-5.

PMID:
15848573
20.

Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.

Cattaneo D, Cortinovis M, Baldelli S, Bitto A, Gotti E, Remuzzi G, Perico N.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1147-55. Epub 2007 Oct 10.

Supplemental Content

Support Center